- Conditions
- Eosinophilic Esophagitis
- Interventions
- Tezepelumab, Placebo
- Biological · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 1,765
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diverticulitis
- Interventions
- High-dose prebiotic, Low-dose prebiotic, Placebo
- Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Treatment Resistant Depression
- Interventions
- BPL-003
- Drug
- Lead sponsor
- Beckley Psytech Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • San Diego, California + 15 more
- Conditions
- Calcium Phosphate Kidney Stones
- Interventions
- OHCit- standard dose, Potassium Citrate, Placebo, OHCit- low dose
- Dietary Supplement · Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Influenza
- Interventions
- Influenza VLP Vaccine (recombinant), Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Pembroke Pines, Florida • Kansas City, Missouri • Warwick, Rhode Island + 1 more
- Conditions
- Nasal Polyposis
- Interventions
- AK001 low dose, AK001 high dose, Placebo
- Drug
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Schizophrenia
- Interventions
- APN1125, Placebo
- Drug
- Lead sponsor
- CoMentis
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Depression
- Interventions
- endotoxin
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Spinal Cord Injury
- Interventions
- Testosterone Gel applied by a pump, Stand Training, Electrical Stimulation
- Drug · Other · Device
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 58 Years · Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- West Orange, New Jersey
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 10
- States / cities
- Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more
- Conditions
- Schizophrenia
- Interventions
- Lurasidone, Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Cerritos, California • Escondido, California + 22 more
- Conditions
- Cocaine Dependence, Opiate Dependence
- Interventions
- Atomoxetine, low dose, Atomoxetine, high dose, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Reproductive Issues
- Interventions
- Vitamin D, Placebo
- Dietary Supplement · Other
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 19 Years to 40 Years · Female only
- Enrollment
- 998 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Research Triangle Park, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Psychology, Social, Inflammation, Defeat, Social, Interaction, Social
- Interventions
- Influenza vaccine, Placebo
- Biological
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Influenza
- Interventions
- VIS410 low dose, VIS410 high dose, Placebo
- Drug
- Lead sponsor
- Visterra, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 11
- States / cities
- Huntsville, Alabama • Coral Gables, Florida • Homestead, Florida + 7 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- SGM-1019, Placebo
- Drug
- Lead sponsor
- Second Genome
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 10
- States / cities
- Chandler, Arizona • Tucson, Arizona • Panorama City, California + 7 more
- Conditions
- Osteoporosis
- Interventions
- LY2541546, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years to 85 Years · Female only
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Gainesville, Georgia • Bethesda, Maryland
- Conditions
- Adenocarcinoma of the Prostate, Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer
- Interventions
- diindolylmethane, placebo, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Crohn Disease, Colitis, Ulcerative
- Interventions
- Tulisokibart, Placebo to tulisokibart
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2037
- U.S. locations
- 12
- States / cities
- Bristol, Connecticut • Ypsilanti, Michigan • Liberty, Missouri + 8 more
- Conditions
- Noise Induced Hearing Loss
- Interventions
- SPI-1005 200mg, SPI-1005 400mg, Placebo
- Drug
- Lead sponsor
- Sound Pharmaceuticals, Incorporated
- Industry
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 5
- States / cities
- Miami, Florida • Kansas City, Kansas • Charleston, South Carolina + 2 more
- Conditions
- Irritability Associated With Autism Spectrum Disorder
- Interventions
- Lumateperone high dose, Lumateperone low dose, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 28 more
- Conditions
- Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
- Interventions
- Intravenous Gemini, Intravenous placebo
- Drug
- Lead sponsor
- Revelation Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 3
- States / cities
- Chula Vista, California • La Mesa, California • San Antonio, Texas
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Interventions
- Tovinontrine (CRD-750), Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 23 more